AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...
Nearly one million Israelis live with chronic lung diseases such as asthma and COPD, and for them the current security ...
Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 ...
People living with chronic obstructive pulmonary disease (COPD) typically rely on maintenance inhalers to manage their daily symptoms. They may also take rescue inhalers for sudden breathing ...
COPD requires regular monitoring through tests like spirometry to assess the condition’s severity and aid in an individualized treatment plan. COPD is a progressive lung condition that makes breathing ...
Recent medical research is reshaping our understanding of Chronic Obstructive Pulmonary Disease (COPD), particularly highlighting its disproportionate impact on women. This shift in the COPD landscape ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results